Profile data is unavailable for this security.
About the company
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as acute migraine and serious lung diseases, such as chronic obstructive pulmonary disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). The Company’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes. The Company’s therapeutic candidates include PUR3100, PUR1800, and PUR1900. PUR3100 is the iSPERSE formulation of dihydroergotamine (DHE), for the treatment of acute migraine.
- Revenue in USD (TTM)7.30m
- Net income in USD-14.12m
- Incorporated2013
- Employees22.00
- LocationPulmatrix Inc36 Crosby Drive, Suite 100BEDFORD 01730United StatesUSA
- Phone+1 (781) 357-2333
- Fax+1 (302) 636-5454
- Websitehttps://www.pulmatrix.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clever Leaves Holdings Inc | 17.42m | -19.80m | 6.73m | 296.00 | -- | 0.2736 | -- | 0.3864 | -12.57 | -11.38 | 11.11 | 14.02 | 0.418 | 1.69 | 11.03 | 58,841.21 | -47.51 | -23.20 | -58.14 | -26.55 | 37.64 | -- | -113.66 | -207.52 | 1.63 | -3.70 | 0.0479 | -- | 6.14 | -- | 47.63 | -- | -- | -- |
| Trevena Inc | 3.13m | -40.29m | 6.78m | 23.00 | -- | -- | -- | 2.17 | -3.16 | -3.16 | 0.2611 | -0.4429 | 0.07 | 3.69 | -- | 135,869.60 | -90.25 | -55.93 | -110.38 | -66.35 | 46.56 | -- | -1,289.25 | -3,134.41 | 4.66 | -15.43 | 1.33 | -- | 847.61 | -11.43 | 24.93 | -- | -24.67 | -- |
| Kineta Inc | 5.44m | -14.10m | 6.96m | 11.00 | -- | 2.28 | -- | 1.28 | -1.43 | -1.43 | 0.5297 | 0.278 | 0.3927 | -- | -- | 494,727.30 | -101.57 | -66.16 | -318.39 | -86.61 | -- | -- | -258.65 | -854.74 | -- | -1,310.25 | 0.2011 | -- | 178.65 | 13.89 | 77.76 | -- | -- | -- |
| Tenax Therapeutics Inc | 0.00 | -7.71m | 6.97m | 5.00 | -- | 0.1311 | -- | -- | -33.51 | -33.51 | 0.00 | 27.15 | 0.00 | -- | -- | 0.00 | -102.20 | -199.16 | -159.72 | -285.64 | -- | -- | -- | -- | -- | -82.13 | 0.0583 | -- | -- | -- | 30.21 | -- | -- | -- |
| Pasithea Therapeutics Corp | 0.00 | -15.51m | 7.05m | 8.00 | -- | 0.3009 | -- | -- | -12.83 | -13.18 | 0.00 | 22.46 | 0.00 | -- | -- | 0.00 | -43.50 | -- | -46.44 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.23 | -- | -- | -- |
| Theriva Biologics Inc | 0.00 | -18.35m | 7.05m | 21.00 | -- | 0.1907 | -- | -- | -1.15 | -1.15 | 0.00 | 2.31 | 0.00 | -- | -- | 0.00 | -28.88 | -36.95 | -32.40 | -40.16 | -- | -- | -- | -- | -- | -- | 0.0056 | -- | -- | -- | 8.37 | -- | 95.91 | -- |
| Plus Therapeutics Inc (USA) | 4.91m | -13.32m | 7.10m | 20.00 | -- | -- | -- | 1.44 | -4.51 | -4.51 | 1.57 | -0.3033 | 0.2787 | -- | -- | 245,650.00 | -75.54 | -59.18 | -210.10 | -133.04 | -- | -- | -271.04 | -470.45 | -- | -- | 1.51 | -- | 2,093.30 | -5.89 | 34.32 | -- | 3.77 | -- |
| Universe Pharmaceuticals Inc | 32.31m | -6.16m | 7.11m | 225.00 | -- | 0.1788 | -- | 0.22 | -1.70 | -1.70 | 8.91 | 10.91 | 0.5727 | 7.93 | 2.50 | 143,594.40 | -10.92 | 5.31 | -14.34 | 7.07 | 31.93 | 46.26 | -19.08 | 6.25 | 2.43 | -28.05 | 0.1218 | 0.00 | -19.52 | 2.53 | 29.46 | -- | -21.17 | -- |
| Biofrontera Inc | 34.07m | -20.13m | 7.35m | 85.00 | -- | 0.4575 | -- | 0.2158 | -15.19 | -15.19 | 24.30 | 3.16 | 0.8646 | 1.93 | 5.42 | 400,858.80 | -51.08 | -- | -101.07 | -- | 48.80 | -- | -59.08 | -- | 0.6727 | -2.71 | 0.4489 | -- | 18.82 | -- | -3,045.47 | -- | -- | -- |
| Pulmatrix Inc | 7.30m | -14.12m | 7.36m | 22.00 | -- | 0.409 | -- | 1.01 | -3.87 | -3.87 | 2.00 | 4.93 | 0.1948 | -- | 6.56 | 331,727.30 | -37.70 | -46.91 | -42.80 | -58.12 | -- | -- | -193.49 | -238.04 | -- | -- | 0.00 | -- | 20.21 | 116.62 | 25.03 | -- | 104.29 | -- |
| Lixte Biotechnology Holdings Inc | 0.00 | -5.09m | 7.54m | 3.00 | -- | 15.23 | -- | -- | -2.77 | -2.77 | 0.00 | 1.78 | 0.00 | -- | -- | 0.00 | -103.09 | -104.18 | -111.07 | -111.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 19.41 | -- | -- | -- |
| Intelligent Bio Solutions Inc | 2.46m | -13.40m | 7.57m | 17.00 | -- | 0.0997 | -- | 3.08 | -131.37 | -131.37 | 20.91 | 26.67 | 0.1831 | 2.41 | 9.09 | 144,726.50 | -99.96 | -80.65 | -157.15 | -224.84 | 20.90 | -- | -545.95 | -948.54 | 0.3864 | -- | 0.1602 | -- | 187.51 | 367.97 | -28.00 | -- | -- | -- |
| Adial Pharmaceuticals Inc | 0.00 | -7.00m | 7.70m | 4.00 | -- | 0.774 | -- | -- | -5.83 | -4.17 | 0.00 | 2.45 | 0.00 | -- | -- | 0.00 | -133.76 | -182.35 | -174.49 | -235.45 | -- | -- | -- | -- | -- | -55.50 | 0.00 | -- | -- | -- | 35.14 | -- | -- | -- |
| Hepion Pharmaceuticals Inc | 0.00 | -48.93m | 7.72m | 22.00 | -- | 1.22 | -- | -- | -12.41 | -12.41 | 0.00 | 1.51 | 0.00 | -- | -- | 0.00 | -124.91 | -61.43 | -150.17 | -68.82 | -- | -- | -- | -- | -- | -4,784.14 | 0.00 | -- | -- | -- | -7.92 | -- | -- | -- |
| Vaccinex Inc | 570.00k | -20.25m | 7.83m | 37.00 | -- | -- | -- | 13.73 | -63.98 | -63.98 | 1.23 | -2.59 | 0.0982 | -- | 1.00 | 15,405.41 | -348.91 | -262.29 | -1,283.74 | -- | -- | -- | -3,552.81 | -4,257.17 | -- | -59.75 | -- | -- | 107.27 | -4.67 | -2.20 | -- | -22.20 | -- |
Data as of Apr 23 2024. Currency figures normalised to Pulmatrix Inc's reporting currency: US Dollar USD
8.33%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Renaissance Technologies LLCas of 31 Dec 2023 | 117.32k | 3.21% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 54.90k | 1.50% |
| Sabby Management LLCas of 31 Dec 2023 | 54.19k | 1.48% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 35.08k | 0.96% |
| Geode Capital Management LLCas of 31 Dec 2023 | 24.66k | 0.68% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 13.95k | 0.38% |
| Tower Research Capital LLCas of 31 Dec 2023 | 3.57k | 0.10% |
| American Portfolios Advisors, Inc.as of 31 Dec 2023 | 175.00 | 0.01% |
| UBS Financial Services, Inc.as of 31 Dec 2023 | 165.00 | 0.01% |
| Arbor Point Advisors LLCas of 31 Dec 2023 | 100.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
